Equities

Nano Mobile Healthcare Inc

VNTH:PKC

Nano Mobile Healthcare Inc

Actions
  • Price (USD)0.0003
  • Today's Change0.00 / 0.00%
  • Shares traded104.44k
  • 1 Year change0.00%
  • Beta-0.2145
Data delayed at least 15 minutes, as of Sep 19 2024 16:33 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Nano Mobile Healthcare Inc had net income fall from a gain of 0.00 to a loss of 1.47k despite flat revenues.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-10,475.82%
Return on equity--
Return on investment--
More ▼

Cash flow in USDView more

Cash flow information is not available for Nano Mobile Healthcare Inc.
Cash flow per share-0.032
Price/Cash flow per share--
Book value per share-0.0129
Tangible book value per share-0.0129
More ▼

Balance sheet in USDView more

Nano Mobile Healthcare Inc uses little or no debt in its capital structure.
Current ratio0.00007
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼

Growth rates in USD

Growth rate information is not available.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
-12,222.04
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.